Skip to main content

Does Scl-Ab change predict pulmonary decline in systemic sclerosis?

Dr. Eric Dein | Abstract 0954 | ACR 2026

Transcription

Hello, this is Eric Dian with RheumNow at day one of ACR Convergence in Orlando, Florida. I'm going to talk about abstract 0954, presented by Eric Robbins et al. from the CONQUER consortium, looking at serum SCL-70 antibodies, or anti-topoisomerase antibodies, and the relevance of tracking them serially to assess for risk of pulmonary decline.

We generally think of looking at these antibodies as binary — present or not present — and usually not something that we're tracking over time. So is there any value in serially monitoring their levels?

They looked at 86 patients who had an SCL-70 test from a commercial lab. Of them, when they used their LIPS testing — which is the luciferase immunoprecipitation systems — they were able to confirm positivity in 74%, or 74 of the 85. 54 of these 74 patients had ILD, as compared to the 20 that did not have ILD. So we know that SCL-70 is a risk factor for ILD, for diffuse skin, for progressive pulmonary decline, and a more severe disease phenotype and poor prognosis.

When they tracked them serially, they checked a baseline with their LIPS lab and then checked it again at 6 months and compared the results. They then looked at the pulmonary function tests between 6 months and 24 months to see if it predicted any form of decline.

When they looked at setting a threshold of a 30% increase in the SCL-70 antibody, they did find that it predicted decline of their pulmonary function testing. In 18 out of the 46 patients that were able to have an analysis, 18 of 46 had that 30% increase, and of those patients 44% of them progressed, as compared to 14% who were progressors in the non-increased group. So that showed these patients with the higher SCL-70 increases over time were more likely to have more progressive ILD. The hazard ratio for this is 3.67.

They did not find significance for other markers like DLCO. Other factors such as modified Rodnan skin score and physician-assessed damage were not found to be statistically significant. The authors do note that the cutoff was fairly arbitrary in doing that greater than 30% increase, and when they looked at it more as a continuous variable, they did not meet significance.

I think this is basis for further investigation. Can we think of anti-SCL-70 antibody as a dynamic prognostic biomarker rather than one static point? Looking at it over time I think will provide us some additional information. For more information on ACR Convergence, tune in to RheumNow for more coverage.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×